A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Portugal- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Largo Professor Abel Salazar, 4050-011 Porto, Portugal
Centro Hospitalar Universitario De Santo Antonio E.P.E. in Porto, Portugal specialises in clinical trials of conditions such as Non-small cell lung cancer, Dermatitis atopic, Crohn's disease, Hidradenitis, and other specialisations. This site conducts important research.
The Centro Hospitalar Universitario De Santo Antonio pediatric neurology team is studying Migraine in children, testing a new biologic therapy to reduce the number of migraine days and improve daily functioning.
With 73 investigators involved, the site in Porto, Portugal, is leading five independent trials aimed at advancing care for pediatric migraine sufferers.
Clinical trials currently enrolling participants at this site.
PortugalOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
PortugalA study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)
PortugalA Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
PortugalStudy of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo
PortugalStudy on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients
PortugalStudy on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy
PortugalStudy of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
PortugalStudy on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis
PortugalStudy of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
PortugalA Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes
PortugalA Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease
PortugalMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.